Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced its participation in several upcoming virtual investing events. Key dates include the Citi’s 16th Annual BioPharma Virtual Conference from September 8-10, with Arrowhead hosting virtual investor meetings on September 9. CEO Chris Anzalone will present during the HC Wainwright 23rd Annual Global Investment Conference on September 13 and the Cantor Virtual Global Healthcare Conference on September 29. These events will showcase Arrowhead's innovative RNA interference therapeutics targeting intractable diseases.
- None.
- None.
Citi’s 16th Annual
HC Wainwright 23rd Annual
Baird's 2021 Global Healthcare Conference –
2021
A copy of the presentation materials and/or live webcast links may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005194/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
646-751-4361
jo@lifescicomms.com
www.lifescicommunications.com
Source:
FAQ
What events is Arrowhead Pharmaceuticals participating in September 2021?
When is Arrowhead's investor meeting scheduled at Citi's conference?
Who will represent Arrowhead at the HC Wainwright conference?
What is the focus of Arrowhead Pharmaceuticals' presentations?
Where can I find more information about Arrowhead Pharmaceuticals' upcoming events?
